Background and Objective: There is marked controversy regarding optimal management patients with stage IB grade III endometrial carcinoma. The present study analyzes the current practices regarding adjuvant radiation therapy for those patients in our institute and also assessed prognostic factor affecting overall survival outcome. Patients and Methods: A total 66 patients with postoperative FIGO stage 1B, grade III endometrial carcinoma were treated and evaluated between the years 2009 and 2014. Risk factors assessed age (<60 versus ≥60), tumor size (≤4 cm versus >4 cm), site of primary tumor (involvement of lower uterine segment versus no involvement), Lymphaden e ctomy (performed versus not performed), Lymph-vascular space invasion (positive or negative), type of surgery performed (less than total abdominal hysterectomy and bilateral salpingo-ophorectomy (TH/BSO) versus greater than or equal TH/BSO), radiation sequence with surgery (no radiation versus adjuvant radiation), and type of radiation (pelvic external beam radiotherapy versus vaginal brachytherapy versus both). Results: Adjuvant radiation therapy after surgery was associated with significantly better time to relapse (p = 0.001) in comparison to those patients who underwent surgery alone. There was statistically significant improvement of survival of patients who received adjuvant radiation therapy in comparison with those who underwent surgery alone. There was no statistically significant difference in relapse between external pelvic radiotherapy, brachytherapy and both (p = 0.161). There was no statistically significant difference in overall survival between different types of adjuvant radiation therapy (p = 0.318). Adjuvant radiation therapy (HR 0.173, 95% CI 0.049 - 0.609, p = 0.006) and tumor size (HR 4.065, 95% CI 1.120 - 14.761, p = 0.033) were the only statistically significant predictors for relapse in multivariate analysis. Adjuvant radiation therapy (HR 0.159, 95% CI 0.045 - 0.563, p = 0.004), age (HR 10.357, 95% CI 1.195 - 89.746, p = 0.034) and lymphadenectomy (HR 0.240, 95% CI 0.071 - 0.811, p = 0.022) were statistically significant predictors for overall survival. Conclusion: The current study suggested that adjuvant radiation therapy definitely improve survival of patients with stage IB, grade III endometrial cancer. There is a need for more randomized trials to define patients who require adjuvant radiation therapy and define what type of radiation should be received. Well defined guidelines are very important to standardize treatment and cut costs in clinical practice.
Lortet-Tieulent, J., Ferlay, J., Bray, F. and Jemal, A. (2018) International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. Journal of the National Cancer Institute, 110, 354-361. https://doi.org/10.1093/jnci/djx214
Lee, N.K., Cheung, M.K., Shin, J.Y., Husain, A., Teng, N.N., Berek, J.S., Kapp, D.S., Osann, K. and Chan, J.K. (2007) Prognostic Factors for Uterine Cancer in Reproductive-Aged Women. Obstetrics & Gynecology, 109, 655-662. https://doi.org/10.1097/01.AOG.0000255980.88205.15
National Cancer Institute Endometrial Cancer Treatment. http://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq
Buhtoiarova, T.N., Brenner, M. and Singh, C.A. (2016) Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. AJCP, 145, 8-21. https://doi.org/10.1093/ajcp/aqv014
Creutzberg, C.L., Nout, R.A., Lybeert, M.L.M., Rodenhuis, C.W., Jobsen, J.J., Mens, J.W., Lutgens, L.C., Elisabeth, P., van de Poll-Franse, L.V. and Van Putten, W.J. (2011) Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma. International Journal of Radiation Oncology, Biology, Physics, 81, e631-e638.
Mutch, D. (2009) The New FIGO Staging System for Cancers of the Vulva, Cervix, Endometrium, and Sarcomas. Gynecologic Oncology, 115, 325-328. https://doi.org/10.1016/j.ygyno.2009.10.050
Keys, H.M., Roberts, J.A., Brunetto, V.L., Zaino, R.J., Spirtos, N.M., Bloss, J.D., Pearlman, A., Maiman, M.A. and Bell, J.G. (2004) A Phase III Trial of Surgery with or without Adjunctive External Pelvic Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology, 92, 744-751.
Bosse, T., Peters, E.E.M., Creutzberg, C.L., urgenliemk-Schulz, I.M., Jobsen, J.J., Mens, J.W.M., Lutgens, L.C.H., van der Steen-Banasik, E.M., Smit, V.T.H. and Nout, R.A. (2015) Substantial Lymph-Vascular Space Invasion (LVSI) Is a Significant Risk Factor for Recurrence in Endometrial Cancer—A Pooled Analysis of PORTEC 1 and 2 Trials. European Journal of Cancer, 51, 1742-1750. https://doi.org/10.1016/j.ejca.2015.05.015
Brachytherapy
Survival
Schink, J.C., Rademaker, A.W., Miller, D.S. and Lurain, J.R. (1991) Tumor Size in Endometrial Cancer. Cancer, 67, 2791-2794. https://doi.org/10.1002/1097-0142(19910601)67:11 3.0.CO;2-S
Klopp, A., Smith, B.D., Alektiar, K., Cabrera, A., Damato, A.L., Erickson, B., Fleming, G., Gaffney, D., Greven, K., Lu, K., Miller, D., Moore, D., Petereit, D., Schefter, T., Small, W., Yashar, C. and Viswanathan, A.N. (2014) The Role of Postoperative Radiation Therapy for Endometrial Cancer: Executive Summary of an American Society for Radiation Oncology Evidence-Based Guideline. Practical Radiation Oncology, 4, 137-144. https://doi.org/10.1016/j.prro.2014.01.003
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M.R. and Sessa, C. (2016) ESMO-ESGOESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up. Annals of Oncology, 27, 16-41. https://doi.org/10.1093/annonc/mdv484
Creasman, W.T., Morrow, C.P., Bundy, B.N., Homesley, H.D., Graham, J.E. and Heller, P.B. (1987) Surgical Pathologic Spread Patterns of Endometrial Cancer: A Gynecologic Oncology Group Study. Cancer, 60, 2035-2041. https://doi.org/10.1002/1097-0142(19901015)60:8+ 3.0.CO;2-8
Blake, P., Swart, A.M., Orton, J., Kitchener, H., Whelan, T., Lukka, H., Eisenhauer, E., Bacon, M., Tu, D., Parmar, M.K., Amos, C., Murray, C. and Qian, W. (2009) Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer (MRC ASTEC and NCIC CTG EN.5 Randomised Trials): Pooled Trial Results, Systematic Review, and Meta-Analysis. The Lancet, 373, 137-146. https://doi.org/10.1016/S0140-6736(08)61767-5
Creutzberg, C.L., van Putten, W.L., Koper, P.C., Lybeert, M.L., Jobsen, J.J., Wárlám-Rodenhuis, C.C., De Winter, K.A., Lutgens, L.C., van den Bergh, A.C., van de Steen-Banasik, E., Beerman, H. and van Lent, M. (2000) Surgery and Postoperative Radiotherapy versus Surgery Alone for Patients with Stage-1 Endometrial Carcinoma: Multicentre Randomised Trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. The Lancet, 355, 1404-1411. https://doi.org/10.1016/S0140-6736(00)02139-5
Kong, A., Johnson, N., Kitchener, H.C. and Lawrie, T.A. (2012) Adjuvant Radiotherapy for Stage I Endometrial Cancer: An Updated Cochrane Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 104, 1625-1634. https://doi.org/10.1093/jnci/djs374
Nout, R.A., Smit, V.T., Putter, H., Jürgenliemk-Schulz, I.M., Jobsen, J.J., Lutgens, L.C., van der Steen-Banasik, E.M., Mens, J.W., Slot, A., Kroese, M.C., van Bunningen, B.N., Ansink, A.C., van Putten, W.L. and Creutzberg, C.L. (2010) Vaginal Brachytherapy versus Pelvic External Beam Radiotherapy for Patients with Endometrial Cancer of High-Intermediate Risk (PORTEC-2): An Open-Label, Non-Inferiority, Randomised Trial. The Lancet, 375, 816-823. https://doi.org/10.1016/S0140-6736(09)62163-2
Sorbe, B., Horvath, G., Andersson, H., Boman, K., Lundgren, C. and Pettersson, B. (2012) External Pelvic and Vaginal Irradiation versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma—A Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics, 82, 1249-1255. https://doi.org/10.1016/j.ijrobp.2011.04.014
de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann. J.A., Khaw, P., Colombo, A., Fyles, A., Baron, M.H., Kitchener, H.C., Nijman, H.W., Kruitwagen, R.F., Nout, R.A., Verhoeven-Adema, K.W., Smit, V.T., Putter, H. and Creutzberg, C.L. (2016) Toxicity and Quality of Life after Adjuvant Chemoradiotherapy versus Radiotherapy Alone for Women with High-Risk Endometrial Cancer (PORTEC-3): An Open-Label, Multicentre, Randomised, Phase 3 Trial. The Lancet Oncology, 17, 1114-1126. https://doi.org/10.1016/S1470-2045(16)30120-6
Rydzewski, N.R., Strohl, A.E., Donnelly, E.D., Kanis, M.J., Lurain, J.R., Nieves-Neira, W. and Strauss, J.B. (2016) Receipt of Vaginal Brachytherapy Is Associated with Improved Survival in Women with Stage I Endometrioid Adenocarcinoma of the Uterus: A National Cancer Data Base Study. Cancer, 122, 3724-3731. https://doi.org/10.1002/cncr.30228
Harkenrider, M.M., Adams, W., Block, A.M., Kliethermes, S., Small Jr., W. and Grover, S. (2017) Improved Overall Survival with Adjuvant Radiotherapy for High-Intermediate and High Risk Stage I Endometrial Cancer. Radiotherapy and Oncology, 122, 452-457. https://doi.org/10.1016/j.radonc.2016.12.003
Wong, A.T., Rineer, J., Schwartz, D., Weiner, J., Safdieh, J., Choi, K. and Schreiber, D. (2017) Patterns of Adjuvant Radiation Usage and Survival Outcomes for Stage I Endometrial Carcinoma in a Large Hospital-Based Cohort. Gynecologic Oncology, 144, 113-118. https://doi.org/10.1016/j.ygyno.2016.11.003
Kong, A., Simera, I., Collingwood, M., Williams, C. and Kitchener, H. (2007) Adjuvant Radiotherapy for Stage I Endometrial Cancer: Systematic Review and Meta-Analysis. Annals of Oncology, 18, 1595-1604. https://doi.org/10.1093/annonc/mdm066
Sorbe, B., Nordstrom, B., Maenpaa, J., Kuhelj, J., Kuhelj, D., Okkan, S., Delaloye, J.F. and Frankendal, B. (2009) Intravaginal Brachytherapy in FIGO Stage I Low-Risk Endometrial Cancer: A Controlled Randomized Study. International Journal of Gynecological Cancer, 19, 873-878. https://doi.org/10.1111/IGC.0b013e3181a6c9df
Crosby, M.A., Tward, J.D., Szabo, A., Lee, C.M. and Gaffney, D.K. (2010) Does Brachytherapy Improve Survival in Addition to External Beam Radiation Therapy in Patients with High Risk Stage I and II Endometrial Carcinoma? American Journal of Clinical Oncology, 33, 364-369.
Kasamatsu, T., Onda, T., Katsumata, N., Sawada, M., Yamada, T., Tsunematsu, R., Ohmi, K., Sasajima, Y. and Matsuno, Y. (2003) Prognostic Significance of Positive Peritoneal Cytology in Endometrial Carcinoma Confined to the Uterus. British Journal of Cancer, 88, 245-250. https://doi.org/10.1038/sj.bjc.6600698
Takeshima, N., Nishida, H., Tabata, T., Hirai, Y. and Hasumi, K. (2001) Positive Peritoneal Cytology in Endometrial Cancer: Enhancement of Other Prognostic Indicators. Gynecologic Oncology, 82, 470-473. https://doi.org/10.1006/gyno.2001.6301
Mariani, A., Webb, M.J., Keeney, G.L., Aletti, G. and Podratz, K.C. (2002) Assessment of Prognostic Factors in Stage IIIA Endometrial Cancer. Gynecologic Oncology, 86, 38-44. https://doi.org/10.1006/gyno.2002.6713
Chino, J.P., Jones, E., Berchuck, A., Secord, A.A. and Havrilesky, L.J. (2012) The Influence of Radiation Modality and Lymph Node Dissection on Survival in Early-Stage Endometrial Cancer. International Journal of Radiation Oncology, Biology, Physics, 82, 1872-1879. https://doi.org/10.1016/j.ijrobp.2011.03.054